Advanced Therapies For Common Conditions In England Won’t Get Extra Funding, Says Ex-NICE Official

 
• By Eliza Slawther
  
NICE bases its payment modifiers on the intended patient population, not the therapy itself
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Cell & Gene Therapies

More from Advanced Technologies